{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:00:54Z","timestamp":1787032854863,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,21]]},"DOI":"10.7759\/cureus.42241","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T05:50:44Z","timestamp":1689918644000},"source":"Crossref","is-referenced-by-count":1,"title":["Retrospective Analysis of the Burden of Illness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Versus Asthma in Commercially Insured US Patients"],"prefix":"10.7759","author":[{"given":"Christopher F","family":"Bell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Ajmera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0736-2","article-title":"Eosinophilic granulomatosis with polyangiitis: newer therapies","volume":"20","author":"Navarro-Mendoza EP","year":"2018","unstructured":"Navarro-Mendoza EP, Tob\u00f3n GJ. Eosinophilic granulomatosis with polyangiitis: newer therapies. Curr Rheumatol Rep. 2018, 20:10.1007\/s11926-018-0736-2","journal-title":"Curr Rheumatol Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette JC","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, et al.. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013, 65:1-11. 10.1002\/art.37715","journal-title":"Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330806","article-title":"The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi AT","year":"1990","unstructured":"Masi AT, Hunder GG, Lie JT, et al.. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990, 33:1094-100. 10.1002\/art.1780330806","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.21002","article-title":"Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States","volume":"27","author":"Bell CF","year":"2021","unstructured":"Bell CF, Blauer-Peterson C, Mao J. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States. J Manag Care Spec Pharm. 2021, 27:1249-59. 10.18553\/jmcp.2021.21002","journal-title":"J Manag Care Spec Pharm"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond C","year":"2013","unstructured":"Comarmond C, Pagnoux C, Khellaf M, et al.. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013, 65:270-81. 10.1002\/art.37721","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management","volume":"26","author":"Groh M","year":"2015","unstructured":"Groh M, Pagnoux C, Baldini C, et al.. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015, 26:545-53. 10.1016\/j.ejim.2015.04.022","journal-title":"Eur J Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001198","article-title":"Prevalence of eosinophilic granulomatosis with polyangiitis and associated health care utilization among patients with concomitant asthma in US commercial claims database","volume":"27","author":"Gokhale M","year":"2021","unstructured":"Gokhale M, Bell CF, Doyle S, Fairburn-Beech J, Steinfeld J, Van Dyke MK. Prevalence of eosinophilic granulomatosis with polyangiitis and associated health care utilization among patients with concomitant asthma in US commercial claims database. J Clin Rheumatol. 2021, 27:107-13. 10.1097\/RHU.0000000000001198","journal-title":"J Clin Rheumatol"},{"key":"ref8","article-title":"Epidemiological study of primary systemic vasculitides among adults in southern Spain and review of the main epidemiological studies","volume":"33","author":"Romero-Gomez C","year":"2015","unstructured":"Romero-Gomez C, Aguilar-Garcia JA, Garcia-de-Lucas MD, et al.. Epidemiological study of primary systemic vasculitides among adults in southern Spain and review of the main epidemiological studies. Clin Exp Rheumatol. 2015, 33:11-8.","journal-title":"Clin Exp Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem107","article-title":"Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden","volume":"46","author":"Mohammad AJ","year":"2007","unstructured":"Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford). 2007, 46:1329-37. 10.1093\/rheumatology\/kem107","journal-title":"Rheumatology (Oxford)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.20077","article-title":"Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate","volume":"51","author":"Mahr A","year":"2004","unstructured":"Mahr A, Guillevin L, Poissonnet M, Aym\u00e9 S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004, 51:92-9. 10.1002\/art.20077","journal-title":"Arthritis Rheum"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05783-8","article-title":"Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis","volume":"40","author":"Jakes RW","year":"2021","unstructured":"Jakes RW, Kwon N, Nordstrom B, Goulding R, Fahrbach K, Tarpey J, Van Dyke MK. Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis. Clin Rheumatol. 2021, 40:4829-36. 10.1007\/s10067-021-05783-8","journal-title":"Clin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roab007","article-title":"The prevalence, burden of disease, and healthcare utilization of patients with eosinophilic granulomatosis with polyangiitis in Japan: a retrospective, descriptive cohort claims database study","volume":"32","author":"Sada KE","year":"2022","unstructured":"Sada KE, Kojo Y, Fairburn-Beech J, Sato K, Akiyama S, Van Dyke MK, Mukai I. The prevalence, burden of disease, and healthcare utilization of patients with eosinophilic granulomatosis with polyangiitis in Japan: a retrospective, descriptive cohort claims database study. Mod Rheumatol. 2022, 32:380-6. 10.1093\/mr\/roab007","journal-title":"Mod Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0","article-title":"Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom","volume":"43","author":"Watts RA","year":"2000","unstructured":"Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000, 43:414-9. 10.1002\/1529-0131(200002)43:2&lt;414::AID-ANR23&gt;3.0.CO;2-0","journal-title":"Arthritis Rheum"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0920-8","article-title":"Treatment of eosinophilic granulomatosis with polyangiitis: a review","volume":"78","author":"Raffray L","year":"2018","unstructured":"Raffray L, Guillevin L. Treatment of eosinophilic granulomatosis with polyangiitis: a review. Drugs. 2018, 78:809-21. 10.1007\/s40265-018-0920-8","journal-title":"Drugs"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates M","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM, et al.. EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016, 75:1583-94. 10.1136\/annrheumdis-2016-209133","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu366","article-title":"Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials","volume":"54","author":"Robson J","year":"2015","unstructured":"Robson J, Doll H, Suppiah R, et al.. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015, 54:471-81. 10.1093\/rheumatology\/keu366","journal-title":"Rheumatology (Oxford)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181af35a5","article-title":"Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis","volume":"88","author":"Neumann T","year":"2009","unstructured":"Neumann T, Manger B, Schmid M, et al.. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore). 2009, 88:236-43. 10.1097\/MD.0b013e3181af35a5","journal-title":"Medicine (Baltimore)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung SA","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, et al.. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021, 73:1366-83. 10.1002\/art.41773","journal-title":"Arthritis Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","author":"Hellmich B","year":"2023","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, et al.. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023, 10.1136\/ard-2022-223764","journal-title":"Ann Rheum Dis"},{"key":"ref20","article-title":"Incremental healthcare costs of eosinophilic granulomatosis with polyangiitis (EGPA) compared to asthma: retrospective analysis of commercial claims data in the United States (US)","volume":"73","author":"Bell C","year":"2021","unstructured":"Bell C, Meyers J, Ajmera M. Incremental healthcare costs of eosinophilic granulomatosis with polyangiitis (EGPA) compared to asthma: retrospective analysis of commercial claims data in the United States (US). Arthritis Rheumatol. 2021, 73:","journal-title":"Arthritis Rheumatol"},{"key":"ref21","unstructured":"Fact Sheet. IQVIA PharMetrics Plus. (2020). Accessed: October 18, 2021: https:\/\/www.iqvia.com\/locations\/united-states\/library\/fact-sheets\/iqvia-pharmetrics-plus."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/pds.913","article-title":"Identification of patients with Churg-Strauss syndrome (CSS) using automated data","volume":"13","author":"Harrold LR","year":"2004","unstructured":"Harrold LR, Andrade SE, Eisner M, et al.. Identification of patients with Churg-Strauss syndrome (CSS) using automated data. Pharmacoepidemiol Drug Saf. 2004, 13:661-7. 10.1002\/pds.913","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4116","article-title":"Development and validation of case-finding algorithms for the identification of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis in large healthcare administrative databases","volume":"25","author":"Sreih AG","year":"2016","unstructured":"Sreih AG, Annapureddy N, Springer J, et al.. Development and validation of case-finding algorithms for the identification of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis in large healthcare administrative databases. Pharmacoepidemiol Drug Saf. 2016, 25:1368-74. 10.1002\/pds.4116","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref24","unstructured":"ICD10CM (International Classification of Diseases, Tenth Revision, Clinical Modification) - Synopsis. (2015). Accessed. June 23, 2021: https:\/\/www.nlm.nih.gov\/research\/umls\/sourcereleasedocs\/current\/ICD10CM\/index.html."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan H","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al.. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011, 173:676-82. 10.1093\/aje\/kwq433","journal-title":"Am J Epidemiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1364","article-title":"Association of patient-centered outcomes with patient-reported and ICD-9-based morbidity measures","volume":"10","author":"Bayliss EA","year":"2012","unstructured":"Bayliss EA, Ellis JL, Shoup JA, Zeng C, McQuillan DB, Steiner JF. Association of patient-centered outcomes with patient-reported and ICD-9-based morbidity measures. Ann Fam Med. 2012, 10:126-33. 10.1370\/afm.1364","journal-title":"Ann Fam Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.01.006","article-title":"The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients","volume":"61","author":"Charlson ME","year":"2008","unstructured":"Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008, 61:1234-40. 10.1016\/j.jclinepi.2008.01.006","journal-title":"J Clin Epidemiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150479","article-title":"Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States","volume":"42","author":"Raimundo K","year":"2015","unstructured":"Raimundo K, Farr AM, Kim G, Duna G. Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States. J Rheumatol. 2015, 42:2383-91. 10.3899\/jrheum.150479","journal-title":"J Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar C","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D, et al.. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009, 68:1827-32. 10.1136\/ard.2008.101279","journal-title":"Ann Rheum Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-017-0409-3","article-title":"The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA","volume":"17","author":"Suruki RY","year":"2017","unstructured":"Suruki RY, Daugherty JB, Boudiaf N, Albers FC. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017, 17:10.1186\/s12890-017-0409-3","journal-title":"BMC Pulm Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.01.039","article-title":"Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma","volume":"129","author":"Ivanova JI","year":"2012","unstructured":"Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol. 2012, 129:1229-35. 10.1016\/j.jaci.2012.01.039","journal-title":"J Allergy Clin Immunol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2015.08.003","article-title":"Utilization and costs of severe uncontrolled asthma in a managed-care setting","volume":"4","author":"Zeiger RS","year":"2016","unstructured":"Zeiger RS, Schatz M, Dalal AA, et al.. Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract. 2016, 4:120-9.e3. 10.1016\/j.jaip.2015.08.003","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S247498","article-title":"Healthcare costs of diabetes and microvascular and macrovascular disease in individuals with incident type 2 diabetes mellitus: a 10-year longitudinal study","volume":"12","author":"Visaria J","year":"2020","unstructured":"Visaria J, Iyer NN, Raval AD, et al.. Healthcare costs of diabetes and microvascular and macrovascular disease in individuals with incident type 2 diabetes mellitus: a 10-year longitudinal study. Clinicoecon Outcomes Res. 2020, 12:423-34. 10.2147\/CEOR.S247498","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rky005","article-title":"Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs","volume":"2","author":"Chen CI","year":"2018","unstructured":"Chen CI, Wang L, Wei W, Yuce H, Phillips K. Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs. Rheumatol Adv Pract. 2018, 2:10.1093\/rap\/rky005","journal-title":"Rheumatol Adv Pract"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S302289","article-title":"Real-world health care resource utilization and costs among US patients with knee osteoarthritis compared with controls","volume":"13","author":"Bedenbaugh AV","year":"2021","unstructured":"Bedenbaugh AV, Bonafede M, Marchlewicz EH, Lee V, Tambiah J. Real-world health care resource utilization and costs among US patients with knee osteoarthritis compared with controls. Clinicoecon Outcomes Res. 2021, 13:421-35. 10.2147\/CEOR.S302289","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191012","article-title":"Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study","volume":"192","author":"Mebrahtu TF","year":"2020","unstructured":"Mebrahtu TF, Morgan AW, West RM, Stewart PM, Pujades-Rodriguez M. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. CMAJ. 2020, 192:295-301. 10.1503\/cmaj.191012","journal-title":"CMAJ"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler ME","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, et al.. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017, 376:1921-32. 10.1056\/NEJMoa1702079","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0099-1","article-title":"Costs of disease relapses among individuals with granulomatosis, with polyangiitis, or microscopic polyangiitis in the United States","volume":"5","author":"Kong AM","year":"2018","unstructured":"Kong AM, Kim G, Michalska M, Best JH. Costs of disease relapses among individuals with granulomatosis, with polyangiitis, or microscopic polyangiitis in the United States. Rheumatol Ther. 2018, 5:159-70. 10.1007\/s40744-018-0099-1","journal-title":"Rheumatol Ther"},{"key":"ref39","unstructured":"NUCALA highlights of prescribing information. (2021). Accessed. August 31, 2021: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL-IFU-COMBINED.PDF."},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld J","year":"2019","unstructured":"Steinfeld J, Bradford ES, Brown J, et al.. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol. 2019, 143:2170-7. 10.1016\/j.jaci.2018.11.041","journal-title":"J Allergy Clin Immunol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka LA","year":"2021","unstructured":"Manka LA, Guntur VP, Denson JL, Dunn RM, Dollin YT, Strand MJ, Wechsler ME. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann Allergy Asthma Immunol. 2021, 126:696-701. 10.1016\/j.anai.2021.01.035","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00451-2020","article-title":"Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis","volume":"6","author":"Nanzer AM","year":"2020","unstructured":"Nanzer AM, Dhariwal J, Kavanagh J, et al.. Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis. ERJ Open Res. 2020, 6:10.1183\/23120541.00451-2020","journal-title":"ERJ Open Res"},{"key":"ref43","unstructured":"International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). (2011). Accessed. June 22, 2021: https:\/\/www.cdc.gov\/nchs\/icd\/icd9cm.htm."},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2005.00444.x","article-title":"Measuring diagnoses: ICD code accuracy","volume":"40","author":"O'Malley KJ","year":"2005","unstructured":"O'Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM. Measuring diagnoses: ICD code accuracy. Health Serv Res. 2005, 40:1620-39. 10.1111\/j.1475-6773.2005.00444.x","journal-title":"Health Serv Res"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.4193\/Rhino14.074","article-title":"Manifestation of eosinophilic granulomatosis with polyangiitis in head and neck","volume":"53","author":"Petersen H","year":"2015","unstructured":"Petersen H, G\u00f6tz P, Both M, et al.. Manifestation of eosinophilic granulomatosis with polyangiitis in head and neck. Rhinology. 2015, 53:277-85. 10.4193\/Rhino14.074","journal-title":"Rhinology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/131309-retrospective-analysis-of-the-burden-of-illness-of-eosinophilic-granulomatosis-with-polyangiitis-egpa-versus-asthma-in-commercially-insured-us-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T15:01:12Z","timestamp":1707490872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/131309-retrospective-analysis-of-the-burden-of-illness-of-eosinophilic-granulomatosis-with-polyangiitis-egpa-versus-asthma-in-commercially-insured-us-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.42241","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,21]]}}}